Search clinical trials for: Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb)

Total 5340 results

Y-mAbs Therapeutics

Terminated

Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers

Osteosarcoma | Neuroblastoma | Other Solid Tumor Cancers

United States
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics; Band of Parents

Completed

Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics

Active, not recruiting

Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics

Active, not recruiting

A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma

Neuroblastoma

United States
Sun Yat-sen University
Hainan General Hospital

Recruiting

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

Neuroblastoma

China
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center; Children's Hospital Los Angeles; Y-mAbs Therapeutics

Active, not recruiting

Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma

Recurrent Osteosarcoma

United States
Memorial Sloan Kettering Cancer Center

Completed

Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics

Active, not recruiting

Study of Chemoimmunotherapy for High-Risk Neuroblastoma

Neuroblastoma (NB)

United States
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics

Active, not recruiting

Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

Neuroblastoma | High-Risk

United States
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Sunshine Lake Pharma Co., Ltd.

Terminated

KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma

Advanced HCC

China
United Therapeutics

Terminated

A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients

Primary Refractory Neuroblastoma

United States
HealthPartners Institute

Completed

Microbiome Changes in Severe Burns (Microbiome)

Burns | Burns Greater Than 20% BSAB

United States
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics

Active, not recruiting

PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study

Melanoma | Sarcoma | Neuroblastoma

United States
Y-mAbs Therapeutics
Children's Oncology Group

Terminated

A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia

AML, Childhood

United States
Margaret Gatti-Mays

Recruiting

Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | HER2-Negative Breast Carcinoma

United States
Binhui Biopharmaceutical Co., Ltd.

Recruiting

oHSV2-PD-L1/CD3-BsAb Administered Via Intramural Injection

Solid Tumor

United States
Memorial Sloan Kettering Cancer Center

Completed

High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation

Neuroblastoma

United States
University Hospital Tuebingen

Available

(Bispecific) Antibodies in Cancer Patients (InHeAb01)

Cancer

Germany
Hoffmann-La Roche

Active, not recruiting

A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus

Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Korea, Republic of, Argentina, Denmark, France, Spain, Brazil, United Kingdom, Turkey, Czechia, Thailand, Russian Federation, Italy, Poland, Taiwan, Singapore, Ukraine, Kenya, Hungary
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center

Completed

3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center

Completed

Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center

Completed

Monoclonal Antibody Therapy in Treating Children With Metastatic Neuroblastoma in Second Remission

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center

Terminated

3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center

Completed

3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center

Completed

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

Sarcoma | Small Intestine Cancer | Ovarian Cancer | Lung Cancer | Brain and Central Nervous System Tumors | Metastatic Cancer | Neuroblastoma | Intraocular Melanoma | Melanoma (Skin) | Retinoblastoma

United States
Memorial Sloan Kettering Cancer Center

Completed

Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

Neuroblastoma | Bone Marrow, Sympathetic Nervous System

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer

Sarcoma | Lung Cancer | Brain and Central Nervous System Tumors | Neuroblastoma | Intraocular Melanoma | Melanoma (Skin) | Retinoblastoma

United States
Memorial Sloan Kettering Cancer Center

Completed

Monoclonal Antibody Therapy Plus Sargramostin in Treating Patients With Advanced Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma

Neuroblastoma

United States
Fudan University

Not yet recruiting

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer (QUEEN-Dream)

Neoadjuvant Therapy | Early Breast Cancer | TNBC, Triple Negative Breast Cancer

China
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment

Neuroblastoma

United States
Hong Kong Children's Hospital
The University of Hong Kong

Recruiting

Quadruple Immunotherapy for Neuroblastoma

Neuroblastoma Recurrent

Hong Kong
Eisai China Inc.

Completed

Efficacy and Safety of Cinitapride Tablets in the Treatment of Mild to Moderate Functional Dyspepsia

Dyspepsia

China
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy Plus Etoposide in Treating Patients With Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma

Brain and Central Nervous System Tumors

United States
Changhai Hospital

Recruiting

Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer

Locally Advanced and Metastatic Pancreatic Cancer

China
Fusion Pharmaceuticals Inc.
AstraZeneca

Not yet recruiting

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

Advanced Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Pancreatic Ductal Adenocarcinoma | Metastatic Colorectal Carcinoma

United States, Canada
Memorial Sloan Kettering Cancer Center

Completed

Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Multiple Therapies in Treating Patients With Advanced Neuroblastoma

Neuroblastoma

United States
SCRI Development Innovations, LLC
Janssen Research & Development, LLC

Recruiting

Outpatient Administration of Teclistamab for Multiple Myeloma

Multiple Myeloma

United States
Qilu Pharmaceutical Co., Ltd.

Recruiting

A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
Shanghai Henlius Biotech

Not yet recruiting

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of HLX35 in Combination With HLX10 in Patients With Advanced or Metastatic Solid Tumors

Solid Tumor, Adult
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Recruiting

Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer

China
Shanghai Henlius Biotech

Recruiting

A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma (HLX301)

Lymphoma | Advanced Tumors | Metastatic Tumors

China
Waterstone Hanxbio Pty Ltd

Recruiting

Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma

Relapsed/Refractory Lymphoma

China
Beijing Mabworks Biotech Co., Ltd.

Recruiting

Phase I Clinical Study of MBS301 in Treatment of HER2 Positive Recurrent or Metastatic Malignant Solid Tumor

HER2-positive Recurrent or Metastatic Malignant Solid Tumor

China

Search clinical trials for: Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations